Research Roundup, April 2025

This blog post is a research roundup of recent publications on eosinophilic diseases, including summaries, links, and citations for the following articles:

Long-Term Research Highlights Diagnostic Challenges and Treatment Outcomes for Patients Across the Netherlands

A multicenter retrospective study conducted in the Netherlands examined 70 patients with non-eosinophilic esophagitis eosinophilic gastrointestinal disorders (EGIDs) over nearly three decades. The research highlighted diagnostic challenges, noting that 61% of patients had normal endoscopy results despite symptoms like diarrhea and abdominal pain. Treatment responses varied, with eosinophilic colitis patients showing the most significant improvement, underscoring the need for standardized diagnostic criteria and more tailored treatment approaches. Learn more.

FDA Reviews GSK’s Depemokimab for Asthma and Nasal Polyps

​GSK’s depemokimab, an ultra-long-acting monoclonal antibody targeting interleukin-5 (IL-5), has been accepted for review by the U.S. Food and Drug Administration (FDA) for two indications: asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, it would be the first biologic therapy for these conditions requiring only twice-yearly dosing. The applications are supported by positive Phase III trial results from the SWIFT and ANCHOR studies, which demonstrated significant clinical benefits with a 26-week dosing interval. Read the press release.

Mepolizumab Efficacy and Safety in Patients with EGPA in Real Practice

A Spanish multicenter study involving patients with eosinophilic granulomatosis with polyangiitis (EGPA) found that long-term treatment with Nucala (mepolizumab) significantly reduced disease activity and allowed many patients to lower or discontinue glucocorticoid use. After six months, nearly half of the patients achieved clinical remission, and over 76% reduced their glucocorticoid dosage, with more than half stopping it entirely. The treatment was well-tolerated, with no severe adverse effects reported, suggesting that Nucala is an effective and safe option for managing EGPA in real-world settings. Learn more.

Segmental Overlap Is Common in Eosinophilic Gastrointestinal Diseases and Impacts Clinical Presentation and Treatment

​A new EGID Partners cohort overlap paper found that segmental overlap in EGIDs is common and significantly influences clinical presentation and treatment. The research revealed that patients with overlapping EGIDs often experience more severe symptoms and require more intensive therapies, such as systemic steroids and biologics. These findings underscore the importance of recognizing overlapping disease patterns to improve diagnosis and personalize treatment strategies. Read the journal summary and view a pdf of the paper and join the EGID Partners Registry here.

Vitamin D Deficiency an Independent Risk Factor in Eosinophilic CRSwNP

A recently published study indicates that vitamin D deficiency is an independent risk factor for eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP). The research found that patients with ECRSwNP had significantly lower serum 25-hydroxyvitamin D levels compared to controls, and those with deficiency had over three times the risk of developing ECRSwNP. Combining vitamin D levels with peripheral eosinophil percentages may serve as a promising biomarker for identifying and managing this condition. Learn more.

Prognostic Value of I-SEE in Eosinophilic Esophagitis

A recent study explored the usefulness of the Index of Severity for Eosinophilic Esophagitis (I-SEE), a tool that measures the severity of eosinophilic esophagitis (EoE). Researchers found that patients with higher I-SEE scores, indicating more severe disease, were less likely to respond well to standard steroid treatments. This suggests that the I-SEE score can help doctors predict which patients might need more aggressive or alternative treatments for EoE. Learn more.